Related Experiment Videos
Microbiological evaluation of cefpodoxime proxetil.
B Wiedemann1, E Luhmer, M T Zühlsdorf
1Department of Pharmaceutical Microbiology, University of Bonn, Federal Republic of Germany.
Drugs
|January 1, 1991
Summary
Cefpodoxime effectively inhibits many bacteria, including streptococci and most Enterobacteriaceae. While generally potent, higher doses may be needed for certain resistant bacteria like Staphylococcus aureus.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Cefpodoxime proxetil is an orally absorbed cephalosporin prodrug.
- Cefpodoxime is the active metabolite, exhibiting broad-spectrum antibacterial activity.
Purpose of the Study:
- To evaluate the in vitro antibacterial spectrum and potency of cefpodoxime.
- To compare cefpodoxime's activity with other oral cephalosporins.
- To assess the potential efficacy of a 200mg dosage regimen.
Main Methods:
- Determination of Minimum Inhibitory Concentrations (MIC50 and MIC90) against various bacterial species.
- Comparative analysis of cefpodoxime activity against Gram-negative and Gram-positive bacteria.
- In vitro modeling of human serum concentrations to predict therapeutic effectiveness.
Main Results:
- Cefpodoxime demonstrated potent activity (MIC ≤ 2 mg/L) against streptococci and most Enterobacteriaceae, with exceptions like Enterobacter cloacae.
- Activity against Staphylococcus aureus was observed at 4 mg/L, with higher MICs for coagulase-negative staphylococci.
- Cefpodoxime showed intermediate activity against Gram-negative bacteria compared to other cephalosporins, but superior activity against staphylococci than some.
- No activity was observed against enterococci.
Conclusions:
- A 200mg cefpodoxime dose is likely sufficient for treating many infections based on in vitro data.
- Further research is required to confirm the efficacy of this dosage for infections caused by bacteria with higher cefpodoxime MICs, such as Staphylococcus aureus.